Developing a nanotechnology-enabled glaucoma device
VisiPlate is designed to treat open-angle glaucoma
VisiPlate is an investigational implant designed to lower intraocular pressure in patients with open-angle glaucoma
Avisi in the news
Next-Gen Avisi Technologies Aims for “One and Done” in a MIGS Device
Some medtech start-ups begin with an inventor with a novel idea; others seek out an unmet clinical need looking for a solution. Avisi Technologies began with market research, that is, a direct appeal to glaucoma specialists to determine what they were missing in their tool kits, and specifically, how the current generation of devices for minimally invasive […]
Avisi Technologies Featured at LSI’s 2024 US Emerging Medtech Summit in Keynote Presentation
Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]
VisiPlate® Aqueous Shunt Safety and Effectiveness data from VITA Clinical Trial to be presented at the 2024 South Africa Glaucoma Society Annual Congress
Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma. REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]